WO2016078854A1 - Préparations contenant de l'acide ascorbique, de l'ubidécarénone et des ions phosphate pour un remodelage amélioré de la peau ou contre la cellulite - Google Patents

Préparations contenant de l'acide ascorbique, de l'ubidécarénone et des ions phosphate pour un remodelage amélioré de la peau ou contre la cellulite Download PDF

Info

Publication number
WO2016078854A1
WO2016078854A1 PCT/EP2015/074202 EP2015074202W WO2016078854A1 WO 2016078854 A1 WO2016078854 A1 WO 2016078854A1 EP 2015074202 W EP2015074202 W EP 2015074202W WO 2016078854 A1 WO2016078854 A1 WO 2016078854A1
Authority
WO
WIPO (PCT)
Prior art keywords
preparations
weight
cosmetic
particularly preferably
total weight
Prior art date
Application number
PCT/EP2015/074202
Other languages
German (de)
English (en)
Inventor
Hülya GÖKSEL
Julia Eckert
Nils Peters
Kerstin Skubsch
Original Assignee
Beiersdorf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beiersdorf Ag filed Critical Beiersdorf Ag
Priority to EP15781683.6A priority Critical patent/EP3221013A1/fr
Publication of WO2016078854A1 publication Critical patent/WO2016078854A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/24—Phosphorous; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35—Ketones, e.g. benzophenone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35—Ketones, e.g. benzophenone
    • A61K8/355—Quinones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A61K8/463—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfuric acid derivatives, e.g. sodium lauryl sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/676—Ascorbic acid, i.e. vitamin C

Definitions

  • the present invention relates to preparations containing ascorbic acid, ubidecarenone and phosphate ions as well as their cosmetic or dermatological use for improved skin contouring or against cellulite.
  • the aim of skin care is also to compensate for the daily loss of fat and water loss of the skin. This is especially important when the natural regeneration capacity is insufficient.
  • skin care products to protect against environmental influences, especially from the sun and wind, and delay the aging of the skin.
  • Exogenous factors such as UV light and chemical noxae, can be cumulatively effective and, for example, accelerate or supplement endogenous aging processes.
  • exogenous factors such as the following structural damage, occur: and dysfunction in the skin beyond the extent and quality of the lesions associated with chronological aging: d) visible vascular dilations (telangiectasias, cuperosis);
  • the present invention relates in particular to products for the care of naturally aged skin, as well as the phenomena listed under a), e) and g).
  • Products for the care of relaxed, especially aged, skin are known per se. They contain e.g. Retinoids (vitamin A acid and / or derivatives thereof) or vitamin A and / or its derivatives. Their effect on the structural damage, however, is limited in scope. In addition, there are significant difficulties in product development in stabilizing the active ingredients sufficiently against oxidative degradation. In addition, the use of vitamin A acid-containing products often causes severe erythematous skin irritation. Retinoids can therefore only be used in low concentrations.
  • Cellulite - a widespread phenomenon - occupies a central position.
  • the visible picture of cellulite is based on an increase in fat deposits in the subcutis (subcutaneous fatty tissue), a weakening of connective tissue and a reduction in the flow conditions in the blood and lymphatic channels.
  • the cause is thus a partial plant-related weakening of the connective tissue with simultaneous occurrence of enlarged fatty cell chambers as a result of obesity, unbalanced diet, lack of exercise.
  • the development of cellulite can also be attributed to an increased permeability of the capillary walls, which allows the penetration of water into the connective tissue.
  • cellulite is a phenomenon that is almost never seen in men.
  • the object of the present invention was therefore to find ways that avoid the disadvantages of the prior art.
  • antioxidants are selected from the group of ascorbic acid and the ascorbyl compounds.
  • Ascorbic acid is an endiol and has a strong reducing effect as a reductone. Ascorbic acid is sensitive to heat and is decomposed in particular in the presence of heavy metal traces and in an alkaline medium by light and atmospheric oxygen, in pure, dry state, however, it is relatively resistant to light, air and heat.
  • Ascorbyl compounds preferably ascorbyl esters of fatty acids, more preferably ascorbyl palmitate, are often used in cosmetic and dermatological preparations, since the sensitivity of these compounds to oxidative influence on ascorbic acid is greatly reduced and these compounds are usually better oil-soluble, which can offer galenic advantages.
  • Ascorbyl compounds in the narrower sense are in particular the ascorbyl esters of the general structure wherein R may represent a branched or unbranched alkyl radical having up to 25 carbon atoms.
  • Ubiquinones serve the organisms as electron carriers in the respiratory chain. They are located in the mitochondria where they anneal the cyclic oxidation and reduction of the substrates. Ubiquinones are characterized by the structural formula
  • Coenzyme Q-10 is characterized by the following structural formula:
  • ubidecaren in skin tightening agents is known per se, for example from EP 1 084 701 A1.
  • An object of the present invention was to eliminate the disadvantages of the prior art.
  • active ingredients or preparations containing such active ingredients should be made available, in the use of which a stimulation of the collagen synthesis, a strengthening of the dermo-epidermal junction zone (skin tightening) and a visible improvement of the skin condition are achieved.
  • the aim was to solve galenic problems and to allow stabilization of vitamin C in the cosmetic formulations.
  • preparations according to the invention for improving the skin surface structure, in particular for smoothing the skin and for reducing skin dews, and in particular the use of preparations according to the invention for the reduction of cellulite, is also considered as an embodiment of the present invention.
  • the phosphate or phosphates are advantageously present in cosmetic or dermatological preparations, preferably at 0.001% by weight to 10% by weight, preferably from 0.05% by weight to 5% by weight. %, particularly preferably from 0.1 to 2.0% by weight, based on the total weight of the preparations. Hydrogen phosphates and dihydrogen phosphates also apply as "phosphate" for the purposes of the present invention.
  • the ascorbyl compound or the ascorbyl compounds, in particular vitamin C is or are advantageously in accordance with the invention in cosmetic or dermatological preparations at 1, preferably at least 2% by weight to 20% by weight, particularly preferably 3% by weight to 5% by weight .-%, based on the total weight of the preparations.
  • One or more compounds from the group of ascorbyl dipalmitate, ascorbic palmitate, sodium ascorbyl phosphate, magnesium ascorbyl phosphate, ascorbyl glucoside, ascorbyl tetraiso palmitate are also advantageous ascorbyl compounds in the context of the present invention.
  • 4-tert-butyl-4'-methoxydibenzoylmethane is advantageously present in cosmetic or dermatological preparations, preferably up to 10% by weight, preferably from 0.05% by weight to 5% by weight, particularly preferably 0.1%. 2.0 wt .-%, based on the total weight of the preparations.
  • concentrations of 0.000,001 ( 10 "6) to 5 wt .-% of coenzyme Q10 (ubidecarenone), preferably from 0.000.1 to 1 wt .-%, particularly preferably 0.001 to 0.5 wt. %, based on the total weight of the preparations.
  • Ubiquinol (also called ubiquinol, or ubiquinol, or QH2 for short) is an electron-rich (reduced) form of coenzyme Q10.
  • the natural ubiquinol form of coenzyme Q10 is 2,3-dimethoxy-5-methyl-6-polyprenyl-1,4-benzoquinol, the polyprenylated side chain being 9-10 units in mammals and 10 units in man.
  • Coenzyme Q10 (CoQ10) exists in three redox states, completely oxidized (ubiquinone-10), partially reduced (semichinone or ibisemiquinone), and completely reduced (ubiquinol).
  • the redox functions of ubiquinol in cellular energy production and in antioxidant protection are based on the ability to exchange two electrons in a redox cycle between ubiquinol (reduced) and the (oxidized) ubiquinone form. It may be advantageous according to the invention to exchange coenzyme Q10 completely or partially for ubiquinol and / or semiquinone.
  • the cell vitality could be increased
  • the dermo-epidermal junction (papillae) is better tightened
  • the active ingredient combinations used according to the invention in cosmetic or dermatological preparations have higher stability than the active ingredients used individually, in particular the ascorbyl compounds and especially the vitamin C.
  • active compound combinations according to the invention as an antioxidant and its use for the control and / or prophylaxis of the oxidative stress induced skin aging and inflammatory reactions.
  • the cosmetic or dermatological preparations according to the invention may be composed as usual and used for the treatment, care and cleansing of the skin and / or the hair and as a make-up product in decorative cosmetics. They preferably contain 0.001% by weight to 10% by weight, preferably 0.05% by weight to 5% by weight, in particular 0.1% to 2.0% by weight, based on the total weight of the preparations, on active compound combinations used according to the invention.
  • complexing agents are known auxiliaries of cosmetology or medical galenics. By complexing of interfering metals such as Mn, Fe, Cu and others, for example, unwanted chemical reactions in cosmetic or dermatological preparations can be prevented.
  • Complexing agents in particular chelators, form complexes with metal atoms, which in the presence of one or more polybasic complexing agents, ie chelators, represent metallacycles.
  • Chelates are compounds in which a single ligand occupies more than one coordination site on a central atom. In this case, normally stretched compounds are closed by complex formation via a metal atom or ion into rings. The number of bound ligands depends on the coordination number of the central metal. The prerequisite for chelation is that the metal-reactive compound contain two or more atomic groups acting as electron donors.
  • the complexing agent (s) can advantageously be selected from the group of the customary compounds, preference being given to at least one substance selected from the group consisting of tartaric acid and its anions, citric acid and its anions, aminopolycarboxylic acids and their anions (such as, for example, ethylenediaminetetraacetic acid (EDTA) and their anions, Nitrilotriacetic acid (NTA) and its anions, hydroxyethylenediaminotriacetic acid (HOEDTA) and its anions, diethyleneaminopentaacetic acid (DPTA) and their anions, trans-1,2-diaminocyclohexanetetraacetic acid (CDTA) and their anions).
  • EDTA ethylenediaminetetraacetic acid
  • NTA Nitrilotriacetic acid
  • HOEDTA hydroxyethylenediaminotriacetic acid
  • DPTA diethyleneaminopentaacetic acid
  • CDTA trans-1,2-diaminocycl
  • the complexing agent (s) according to the invention are advantageously present in cosmetic or dermatological preparations, preferably at from 0.01% by weight to 10% by weight, preferably from 0.05% by weight to 5% by weight, particularly preferably 0.1 - 2.0 wt .-%, based on the total weight of the preparations.
  • Cosmetic and dermatological preparations are applied according to the invention in the usual manner for cosmetics on the skin and / or hair in sufficient quantity.
  • Cosmetic and dermatological preparations according to the invention can be present in various forms. For example, they may contain a solution, an anhydrous preparation, an emulsion or microemulsion of the water-in-oil (W / O) type or of the oil-in-water (O / W) type, a multiple emulsion, for example water-type. in-oil-in-water (W / O / W), a gel, a solid stick, an ointment or even an aerosol.
  • isoquercitrin in encapsulated form, for example in collagen matrices and other conventional encapsulation materials, for example as cellulose encapsulations, in gelatin, wax matrices or liposomally encapsulated.
  • wax matrices as described in DE-OS 43 08 282 have been found to be favorable.
  • the cosmetic and dermatological preparations according to the invention may comprise cosmetic adjuvants such as are conventionally used in such preparations, e.g. Preservatives, bactericides, perfumes, foaming inhibitors, colorants, pigments having a coloring effect, thickeners, surface-active substances, emulsifiers, softening, moistening and / or moisturizing substances, fats, oils, waxes or other conventional ingredients of a cosmetic or cosmetic dermatological formulation such as alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents or silicone derivatives.
  • cosmetic adjuvants such as are conventionally used in such preparations, e.g. Preservatives, bactericides, perfumes, foaming inhibitors, colorants, pigments having a coloring effect, thickeners, surface-active substances, emulsifiers, softening, moistening and / or moisturizing substances, fats, oils, waxes or other conventional ingredients of a cosmetic or cosmetic dermatological formulation such as alcohol
  • compounds according to the invention may also contain further antioxidants and / or radical scavengers.
  • antioxidants are advantageously selected from the group consisting of amino acids (eg glycine, histidine, tyrosine, tryptophan) and their derivatives, imidazoles (eg urotanic acid) and their derivatives, peptides such as D, L-carnosine, D-carnosine, L-carnosine.
  • amino acids eg glycine, histidine, tyrosine, tryptophan
  • imidazoles eg urotanic acid
  • peptides such as D, L-carnosine, D-carnosine, L-carnosine.
  • Carnosine and its derivatives eg anserine
  • carotenoids eg ⁇ -carotene, ⁇ -carotene, lycopene
  • chlorogenic acid and its derivatives lipoic acid and its derivatives (eg dihydrolipoic acid), aurothioglucose
  • propylthiouracil and other thiols eg Thioredoxin, glutathione, cysteine, cystine, cystamine and their glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, oleyl, ⁇ -linoleyl, Cholesteryl and glyceryl esters
  • dilauryl thiodipropionate distearyl thiodipropionate
  • thiodipropionic acid and derivatives thereof esters, ethers, peptide
  • the amount of the aforementioned antioxidants (one or more compounds) in the preparations is preferably 0.001 to 30 wt .-%, particularly preferably 0.05 to 20 wt .-%, in particular 0.1 to 10 wt .-%, based on the Total weight of the preparation.
  • vitamin E and / or its derivatives represent the additional antioxidant (s)
  • vitamin A or vitamin A derivatives, or carotenes or derivatives thereof constitute the additional antioxidant (s)
  • their respective concentrations are in the range from 0.001 to 10% by weight, based on the total weight of the formulation , to choose.
  • Emulsions according to the invention are advantageous and contain, for example, the said fats, oils, waxes and other fatty substances, as well as water and an emulsifier, as is customarily used for such a type of formulation.
  • the lipid phase can advantageously be selected from the following substance group: mineral oils, mineral waxes
  • Oils such as triglycerides of capric or caprylic acid, further natural oils such as e.g. Castor oil, almond oil,
  • Fats, waxes and other natural and synthetic fats preferably esters of fatty acids with lower C-number alcohols, e.g. with isopropanol, propylene glycol or glycerol, or esters of fatty alcohols with alkanoic acids of low C number or with fatty acids;
  • Silicone oils such as dimethylpolysiloxanes, diethylpolysiloxanes, diphenylpolysiloxanes and mixed forms thereof.
  • the oil phase of the emulsions, oleogels or hydrodispersions or lipodispersions in the context of the present invention is advantageously selected from the group of esters of saturated and / or unsaturated, branched and / or unbranched alkanecarboxylic acids having a chain length of 3 to 30 carbon atoms and saturated and / or or unsaturated, branched and / or unbranched alcohols having a chain length of 3 to 30 carbon atoms, from the group of esters of aromatic carboxylic acids and saturated and / or unsaturated, branched and / or unbranched alcohols having a chain length of 3 to 30 carbon atoms.
  • ester oils can then advantageously be selected from the group isopropyl myristate, isopropyl palmitate, isopropyl stearate, isopropyl oleate, n-butyl stearate, n-hexyl laurate, n-decyl oleate, isooctyl stearate, isononyl stearate, isononyl isononanoate, 2-ethylhexyl palmitate, 2-ethylhexyl laurate, 2-hexyldecyl stearate, 2 Octyldodecyl palmitate, oleyl oleate, oleyl erucate, erucyl oleate, erucyl erucate and synthetic, semi-synthetic and natural mixtures of such esters, eg Jojoba oil.
  • the oil phase can be advantageously selected from the group of branched and unbranched hydrocarbons and waxes, the silicone oils, the dialkyl ethers, the group of saturated or unsaturated, branched or unbranched alcohols, and the fatty acid triglycerides, in particular the triglycerol esters of saturated and / or unsaturated, branched and / or unbranched alkanecarboxylic acids of a chain length of 8 to 24, in particular 12 to 18 carbon atoms.
  • the fatty acid triglycerides can be selected, for example, advantageously from the group of synthetic, semi-synthetic and natural oils, eg Olive oil, sunflower oil, soybean oil, peanut oil, rapeseed oil, almond oil, palm oil, coconut oil, palm kernel oil, and the like.
  • synthetic, semi-synthetic and natural oils eg Olive oil, sunflower oil, soybean oil, peanut oil, rapeseed oil, almond oil, palm oil, coconut oil, palm kernel oil, and the like.
  • any mixtures of such oil and wax components are also advantageous to use in the context of the present invention. It may also be advantageous, if appropriate, to use waxes, for example cetyl palmitate, as the sole lipid component of the oil phase.
  • the oil phase is selected from the group consisting of 2-ethylhexyl isostearate, octyldodecanol, isotridecyl isononanoate, isoeicosane, 2-ethylhexyl cocoate, C 12-15 -alkyl benzoate, caprylic-capric triglyceride, dicaprylyl ether.
  • Particularly advantageous are mixtures of C 12-15 -alkyl benzoate and 2-ethylhexyl isostearate, mixtures of C 12-18 -alkyl benzoate and isotridecyl isononanoate and also mixtures of C 12-15 -alkyl benzoate, 2-ethylhexyl isostearate and isotridecyl isononanoate.
  • hydrocarbons paraffin oil, squalane and squalene are to be used advantageously in the context of the present invention.
  • the oil phase may further comprise a content of cyclic or linear silicone oils or consist entirely of such oils, although it is preferred to use an additional content of other oil phase components in addition to the silicone oil or silicone oils.
  • Dimethicone is advantageously used as the silicone oil to be used according to the invention.
  • other silicone oils are also advantageous for the purposes of the present invention, for example hexamethylcyclotrisiloxane, polydimethylsiloxane, poly (methylphenylsiloxane).
  • the aqueous phase of the preparations according to the invention optionally advantageously contains alcohols, diols or polyols of low C number, and their ethers, preferably ethanol, isopropanol, propylene glycol, glycerol, ethylene glycol, ethylene glycol monoethyl or -mob nobutyl ether, propylene glycol monomethyl, -monoethyl- or monobutyl ether , Diethylene glycol monomethyl or monoethyl ether and analogous products, furthermore low-C alcohols, for example ethanol, isopropanol, 1,2-propanediol, glycerol and, in particular, one or more thickeners, which may advantageously be selected from the group silicon dioxide, Aluminum silicates, polysaccharides or their derivatives, for example hyaluronic acid, xanthan gum, hydroxypropylmethylcellulose, particularly advantageously from Group of polyacrylates, preferably a polyacrylate from
  • mixtures of the abovementioned solvents are used.
  • alcoholic solvents water can be another ingredient.
  • Emulsions of the invention are advantageous and contain e.g. the said fats, oils, waxes and other fatty substances, as well as water and an emulsifier, as commonly used for such a type of formulation.
  • Gels according to the invention usually contain low C number alcohols, e.g. Ethanol, isopropanol, 1, 2-propanediol, glycerol and water or an above-mentioned oil in the presence of a thickener which is preferably silica or an aluminosilicate in oily-alcoholic gels, in aqueous-alcoholic or alcoholic gels preferably a polyacrylate.
  • low C number alcohols e.g. Ethanol, isopropanol, 1, 2-propanediol, glycerol and water or an above-mentioned oil in the presence of a thickener which is preferably silica or an aluminosilicate in oily-alcoholic gels, in aqueous-alcoholic or alcoholic gels preferably a polyacrylate.
  • Suitable propellants for preparations which can be sprayed from aerosol containers according to the invention are the customary known highly volatile, liquefied propellants, for example hydrocarbons (propane, butane, isobutane), which can be used alone or mixed with one another. Also, compressed air is advantageous to use.
  • preparations according to the invention may also contain other substances which absorb UV radiation in the UVA and / or UVB range, the total amount of filter substances being e.g. 0.1 wt .-% to 30 wt .-%, preferably 0.5 to 10 wt .-%, in particular 1, 0 to 6.0 wt .-%, based on the total weight of the preparations to cosmetic preparations for To provide the hair or the skin against the entire range of ultraviolet radiation. They can also serve as a sunscreen for hair or skin.
  • UVB filter substances may be oil-soluble or water-soluble.
  • oil-soluble UVB filters according to the invention are, for example:
  • benzylidenecamphor 4-aminobenzoic acid derivatives, preferably (2- ethylhexyl) 4- (dimethylamino) benzoate, 4- (dimethylamino) benzoic acid amyl ester;
  • Esters of cinnamic acid preferably 4-methoxycinnamic acid (2-ethylhexyl) ester, 4-methoxycinnamic acid isopentyl ester;
  • esters of salicylic acid preferably 2-ethylhexyl salicylate, 4-isopropylbenzyl salicylate, homomenthyl salicylate,
  • benzophenone preferably 2-hydroxy-4-methoxybenzophenone, 2-hydroxy-4-methoxy-4'-methylbenzophenone, 2,2'-dihydroxy-4-methoxybenzophenone;
  • Esters of benzalmalonic acid preferably di (2-ethylhexyl) 4-methoxybenzalmalonate, - 2,4,6-trianilino (p-carbo-2'-ethyl-1 '-hexyloxy) -1, 3,5-triazine.
  • Advantageous water-soluble UVB filters are, for example:
  • Salts of 2-phenylbenzimidazole-5-sulfonic acid such as its sodium, potassium or triethanolammonium salt, and the sulfonic acid itself;
  • Sulfonic acid derivatives of benzophenones preferably 2-hydroxy-4-methoxybenzophenone-5-sulfonic acid and its salts;
  • Sulfonic acid derivatives of the 3-benzylidene camphor e.g. 4- (2-oxo-3-bomylidene-methyl) benzenesulfonic acid, 2-methyl-5- (2-oxo-3-bomylidenemethyl) sulfonic acid and its salts, and the 1,4-di (2-oxo-10-sulfonic acid) 3-bornylidenemethyl) benzene and its salts (the debasing 10-sulfato compounds, for example the corresponding sodium, potassium or triethanolammonium salt), also as benzene-1,4-di (2-oxo-3-bornyli) denmethyl-10-sulfonic acid
  • UVB filters which can be used in combination with the active compound combinations according to the invention should of course not be limiting.
  • the invention also provides the use of a combination of the active substance combinations used according to the invention with at least one UVB filter as antioxidant or the use of a combination of the active compound combinations used according to the invention with at least one UVB filter as antioxidant in a cosmetic or dermatological preparation. It may also be advantageous to combine the active ingredient combinations used according to the invention with UVA filters which have hitherto usually been present in cosmetic preparations.
  • Cosmetic and dermatological preparations with an effective content of active ingredient combinations used according to the invention may also contain inorganic pigments which are commonly used in cosmetics for the protection of the skin from UV rays. These are oxides of titanium, zinc, zirconium, silicon, manganese, cerium and mixtures thereof, as well as modifications in which the oxides are the active agents. Particular preference is given to pigments based on titanium dioxide.
  • the EU Commission published a recommendation aimed at increasing the safety and transparency of sunscreen products.
  • the EU recommendation provides for UVA protection of 1: 3 in relation to UVB protection.
  • Beiersdorf AG developed an in-vitro method for UVA determination as a function of the sun protection factor: the UVA / UVB balance.
  • the UVA / UVB balance is the basis of the method discussed there. It is modified to include a pre-irradiation with UV light to include some special UV filter systems. So far, the products have been tested without pre-irradiation.
  • UVA filters are used in relation of 1: 3 to UVB filters, and thus the UVA protection is increased with increasing light protection.
  • the ratio of UV-A to UV-B protection is at least 1: 3, more preferably at least 2: 3.
  • the cosmetic and dermatological ingredients include active ingredients and adjuvants commonly used for this type of hair care and hair treatment preparations.
  • auxiliaries are preservatives, surface-active substances, substances for preventing the foaming, thickeners, emulsifiers, fats, oils, waxes, organic solvents, bactericides, perfumes, dyes or pigments whose task is the hair or the cosmetic or dermatological preparation itself dye, Elektroyte, substances against the greasing of the hair.
  • Procollagen is synthesized and secreted in fibroblasts as a precursor to collagen. When converted into collagen, propeptides are cleaved off. The concentration of the procollagen peptide is thus a measure of the synthesis of the collagen.
  • the Prokollagen Type I C-peptide (PIP) EIA Kit is an in vitro enzyme immunoassay (EIA) kit for the quantitative determination of PIP in cell culture supernatants. An increase in per collagen level by drug addition compared to untreated control indicates the drug has a positive impact on the prokollagen synthesis of skin cells in vitro.
  • Untreated cells serve as controls, and are set equal to 100% in the evaluation.
  • MTT Evidence of cell vitality by MTT assay is based on the reduction of a yellow, water-soluble dye 3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide (MTT) into a blue-violet, water-insoluble formazan salt. This reduction is mainly dependent on the pyridine-containing reduction equivalents NADH and NADPH and. The amount of dye reacted and ultimately measured thus corresponds to the glycolytic rate of the cell.
  • MTT 4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide
  • Untreated cells serve as controls, and are set equal to 100% in the evaluation. At a concentration of 100 ⁇ vitamin C in combination with 0.4 ⁇ Q10 an increase of 5.7% is visible compared to the untreated control (see Fig. 2)
  • MIF Macrophage Migration Inhibitory Factor
  • 3 human fibroblast target lines were incubated with active ingredient over a period of 24 hours.
  • the medium is removed and the cells are incubated for 20 minutes at room temperature in PBS.
  • fresh medium containing the substance to be tested is added to the cells.
  • Untreated cells serve as controls, and are set equal to 100% in the evaluation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)

Abstract

Préparations, en particulier préparations cosmétiques ou dermatologiques, contenant a) au moins 0,5% en poids, de préférence au moins 2% en poids d'acide ascorbique et/ou de composés ascorbylés par rapport au poids total des préparations, b) un ou plusieurs phosphates hydrosolubles, en particulier des orthophosphates, c) facultativement, du 4-tert-butyl-4'-méthoxydibenzoylméthane, d) de l'ubidécarénone (co-enzyme Q10)..
PCT/EP2015/074202 2014-11-19 2015-10-20 Préparations contenant de l'acide ascorbique, de l'ubidécarénone et des ions phosphate pour un remodelage amélioré de la peau ou contre la cellulite WO2016078854A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP15781683.6A EP3221013A1 (fr) 2014-11-19 2015-10-20 Préparations contenant de l'acide ascorbique, de l'ubidécarénone et des ions phosphate pour un remodelage amélioré de la peau ou contre la cellulite

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102014223570.7 2014-11-19
DE102014223570.7A DE102014223570A1 (de) 2014-11-19 2014-11-19 Zubereitungen mit einem Gehalt an Ascorbinsäure, Ubidecarenon und Phosphationen zur verbesserten Hautkonturierung bzw. gegen Cellulite

Publications (1)

Publication Number Publication Date
WO2016078854A1 true WO2016078854A1 (fr) 2016-05-26

Family

ID=54330781

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2015/074202 WO2016078854A1 (fr) 2014-11-19 2015-10-20 Préparations contenant de l'acide ascorbique, de l'ubidécarénone et des ions phosphate pour un remodelage amélioré de la peau ou contre la cellulite

Country Status (4)

Country Link
EP (1) EP3221013A1 (fr)
DE (1) DE102014223570A1 (fr)
MA (1) MA40966A (fr)
WO (1) WO2016078854A1 (fr)

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4308282A1 (de) 1993-03-16 1994-09-22 Beiersdorf Ag Vorzugsweise in Form von Mikrosphärulen vorliegende galenische Matrices
EP1084701A1 (fr) 1999-09-15 2001-03-21 Beiersdorf Aktiengesellschaft Emulsion H/E contenant un ou plusieurs bioquinones et un teneur de glycerine élevée
DE10020874A1 (de) * 2000-04-28 2001-05-17 Murnauer Markenvertrieb Gmbh Kosmetisch-pharmazeutisches Kombinationspräparat
KR20040085825A (ko) * 2003-04-01 2004-10-08 주식회사 인 바이오넷 비타민ｃ-안정화 액상 조성물
WO2007013633A1 (fr) * 2005-07-27 2007-02-01 Showa Denko K.K. Préparation émulsifiée à usage externe pour la peau et procédé servant à stabiliser la préparation à usage externe pour la peau
US20070196310A1 (en) * 2006-02-21 2007-08-23 Mary Kay Inc. Stable vitamin c compositions
US20080249192A1 (en) * 2004-04-05 2008-10-09 Caroline Goget Wax Mixture Based on Partial Glycerides and Pentaerythriol Esters
US20090110671A1 (en) * 2005-08-11 2009-04-30 Satomi Miyata Agent for enhanching the production of collagen and it's use
US20110166222A1 (en) * 2010-01-05 2011-07-07 Kaplan David L Vitamin c composition for use in the prevention and treatment of stretch marks, radiation dermatitis, and other skin conditions and methods of using the same
WO2012086341A1 (fr) * 2010-12-24 2012-06-28 ライオン株式会社 Composition liquide à usage oral
US20120195946A1 (en) * 2010-08-03 2012-08-02 Andrey Semechkin Topical Skin Care Compositions and Methods
RU2011106808A (ru) * 2011-02-24 2012-08-27 Общество с ограниченной ответственностью "ДИНАМИК ДЕВЕЛОПМЕНТ ЛАБОРАТОРИЗ" (RU) Композиция, обладающая адаптогенным, общеукрепляющим и повышающим работоспособность действием
US20130045173A1 (en) * 2008-02-08 2013-02-21 Shisedio Company Ltd. Method For Inhibiting Melanin Production And Whitening Skin With Pyrimidlypyrazole Compounds Or Pharmaceutically Acceptable Salts Thereof
WO2014183973A1 (fr) * 2013-05-14 2014-11-20 Beiersdorf Ag Préparations stabilisées à teneur en acide ascorbique et en ions phosphate
WO2014183974A1 (fr) * 2013-05-14 2014-11-20 Beiersdorf Ag Préparations stabilisées à teneur en acide ascorbique, et mélanges de sodium stéaroyl glutamate et/ou de cétyl stéaryl sulfate en association avec du glycéryl stéarate

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02209807A (ja) * 1989-02-09 1990-08-21 Takeda Chem Ind Ltd 抗炎症剤
JP4205226B2 (ja) * 1998-12-03 2009-01-07 日本ゼトック株式会社 細胞賦活剤、それを含む皮膚外用剤及び皮膚洗浄剤
JP2003277219A (ja) * 2002-03-20 2003-10-02 Sukoyaka Shokuhin Kk 化粧用植物オイルおよびクリームの、しわ、しみ改善、老人性いぼ、ほくろ縮小、ほか、皮膚の状態改善効果強化にかかわる方法
DE10234885B4 (de) * 2002-07-31 2005-03-10 Beiersdorf Ag Kosmetische und/oder dermatologische Silikon-in Wasser-Emulsionen und transparentes Packmittel enthaltend diese Sonnenschutzzubereitungen
KR20070103173A (ko) * 2006-04-18 2007-10-23 영진약품공업주식회사 코엔자임 ｑ10을 포함하는 피부보호 조성물

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4308282A1 (de) 1993-03-16 1994-09-22 Beiersdorf Ag Vorzugsweise in Form von Mikrosphärulen vorliegende galenische Matrices
EP1084701A1 (fr) 1999-09-15 2001-03-21 Beiersdorf Aktiengesellschaft Emulsion H/E contenant un ou plusieurs bioquinones et un teneur de glycerine élevée
DE10020874A1 (de) * 2000-04-28 2001-05-17 Murnauer Markenvertrieb Gmbh Kosmetisch-pharmazeutisches Kombinationspräparat
KR20040085825A (ko) * 2003-04-01 2004-10-08 주식회사 인 바이오넷 비타민ｃ-안정화 액상 조성물
US20080249192A1 (en) * 2004-04-05 2008-10-09 Caroline Goget Wax Mixture Based on Partial Glycerides and Pentaerythriol Esters
WO2007013633A1 (fr) * 2005-07-27 2007-02-01 Showa Denko K.K. Préparation émulsifiée à usage externe pour la peau et procédé servant à stabiliser la préparation à usage externe pour la peau
US20090110671A1 (en) * 2005-08-11 2009-04-30 Satomi Miyata Agent for enhanching the production of collagen and it's use
US20070196310A1 (en) * 2006-02-21 2007-08-23 Mary Kay Inc. Stable vitamin c compositions
US20130045173A1 (en) * 2008-02-08 2013-02-21 Shisedio Company Ltd. Method For Inhibiting Melanin Production And Whitening Skin With Pyrimidlypyrazole Compounds Or Pharmaceutically Acceptable Salts Thereof
US20110166222A1 (en) * 2010-01-05 2011-07-07 Kaplan David L Vitamin c composition for use in the prevention and treatment of stretch marks, radiation dermatitis, and other skin conditions and methods of using the same
US20120195946A1 (en) * 2010-08-03 2012-08-02 Andrey Semechkin Topical Skin Care Compositions and Methods
WO2012086341A1 (fr) * 2010-12-24 2012-06-28 ライオン株式会社 Composition liquide à usage oral
RU2011106808A (ru) * 2011-02-24 2012-08-27 Общество с ограниченной ответственностью "ДИНАМИК ДЕВЕЛОПМЕНТ ЛАБОРАТОРИЗ" (RU) Композиция, обладающая адаптогенным, общеукрепляющим и повышающим работоспособность действием
WO2014183973A1 (fr) * 2013-05-14 2014-11-20 Beiersdorf Ag Préparations stabilisées à teneur en acide ascorbique et en ions phosphate
WO2014183974A1 (fr) * 2013-05-14 2014-11-20 Beiersdorf Ag Préparations stabilisées à teneur en acide ascorbique, et mélanges de sodium stéaroyl glutamate et/ou de cétyl stéaryl sulfate en association avec du glycéryl stéarate

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Colipa Guidlines", 2007, article "Method for the in vitro determination of UVA protection provided by sunscreen products"
DATABASE WPI 2011 Derwent World Patents Index; AN 2013-A39472, XP002750944, "Composition, useful as adaptogenic substance for health-improving action, comprises e.g. dipotassium hydrogen phosphate, nicotinamide, calcium pantothenate, inositol choline, riboflavin, carotene, folic acid, biotin, fructose and sweetener" *

Also Published As

Publication number Publication date
DE102014223570A1 (de) 2016-05-19
MA40966A (fr) 2017-09-26
EP3221013A1 (fr) 2017-09-27

Similar Documents

Publication Publication Date Title
DE10032964B4 (de) Verwendung von Kreatin in kosmetischen oder dermatologischen Zubereitungen
EP0716847A1 (fr) Compositions cosmétiques ou dermatologiques contenant des dérivés d'acide cinnamique et des flavonoides
EP1194115A1 (fr) Agent pour usage topique a action protectrice et regeneratrice, comprenant de l'idebenone
DE10342212A1 (de) Verwendung von Licocalchon A oder eines Licocalchon A enthaltenden Extraktes aus Radix Glycyrrhizae inflatae gegen Hautalterung
DE10136077A1 (de) Kosmetische oder dermatologische Zubereitungen mit einer Kombination von Kreatinin und/oder Kreatininderivaten mit Kreatin und/oder seinen Derivaten
WO2014183973A1 (fr) Préparations stabilisées à teneur en acide ascorbique et en ions phosphate
DE102005035864A1 (de) Verwendung von Xanthohumol und/oder Isoxanthohumol zur Herstellung von kosmetischen oder dermatologischen Zubereitungen zur Behandlung und/oder Prophylaxe der Symptome der intrinsischen und/oder extrinsischen Hautalterung sowie zur Behandlung und Prophylaxe der schädlichen Auswirkungen ultravioletter Strahlung auf die Haut
DE102004032837A1 (de) Verwendung von Wirkstoffkombinationen aus einem oder mehreren Biochinonen und einem oder mehreren Isoflavonen zur Verbesserung der Hautkonturen
EP1733741A2 (fr) Emulsion H/E contenant un ou plusieurs bioquinones et un teneur de glycerine élevée
EP1214927A1 (fr) Utilisation de l' acide folique et/ou de ses dérivés pour la préparation de compositions topiques
EP1414401A1 (fr) Utilisation de creatinine et/ou de derives de la creatinine dans des preparations cosmetiques ou dermatologiques
WO2016078853A1 (fr) Préparations contenant de l'acide ascorbique, de l'ubidécarénone et un mélange émulsifiant
EP1000603B1 (fr) Utilisation d'esters tensioactifs d'acide citrique pour stabiliser de flavones, flavanones ou de flavonoides et mélanges synergiques, compositions cosmétiques et dermatologiques les contenant
DE102013208880A1 (de) Stabilisierte Zubereitungen mit einem Gehalt an Ascorbinsäure und Gemischen aus Natriumstearoylglutamat und/oder Cetylstearylsulfat in Kombination mit Glycerylstearat
WO2002098386A2 (fr) Utilisation de polystyrene sulfonate de sodium pour raffermir la peau
EP2421502B1 (fr) COMPOSITION COMPRENANT l'ACIDE GLYCYRRHÉTINIQUE POUR RÉPARER DES DOMMAGES DÉJÀ SUBIS PAR L'ADN DE LA PEAU
WO2016078854A1 (fr) Préparations contenant de l'acide ascorbique, de l'ubidécarénone et des ions phosphate pour un remodelage amélioré de la peau ou contre la cellulite
DE10316666B4 (de) Kosmetische oder dermatologische Zubereitungen mit einer Kombination von Kreatinin mit Kreatin und Coenzym Q10
DE10121069A1 (de) Verwendung von Tetrahydrocurcuminoiden oder deren Derivaten als Wirkstoffe zur Herstellung von kosmetischen und dermatologischen Zubereitungen zum Schutz und zur Behandlung der trockenen bzw. alterstrockenen Haut
WO2003030992A1 (fr) Produits cosmetiques contenant des betaines
DE102012214034A1 (de) Verwendung von Wirkstoffkombinationen aus Harnstoff und Carnitin und/oder einem oder mehreren Acyl-Carnitinen zur Verbesserung der Hautkonturen
WO2021104781A1 (fr) Combinaisons de principes actifs d'ubiquinol et d'ubiquinone, préparations cosmétiques ou dermatologiques contenant de telles combinaisons de principes actifs, et utilisation d'ubiquinol pour améliorer l'efficacité de préparations cosmétiques ou dermatologiques à teneur en ubiquinone
DE10158076B4 (de) Kosmetische und/oder dermatologische Zubereitungen mit einem Gehalt an Aryl-Ureido-Verbindungen und ihre Verwendung
DE19615576A1 (de) Verfahren zur Herstellung von Mono- und/oder Diglucosiden des Glabridins und deren Verwendung als antiirritativer Wirkstoff in kosmetischen und topischen dermatologischen Zubereitungen
EP3644953A1 (fr) Utilisation de n-(4-amino-2-méthylchinolin-6-yl)-2-((4-éthylphénoxy)méthyl)benzamide pour produire des préparations cosmétiques ou dermatologiques destinées au traitement thérapeutique et/ou prophylactique des symptômes du vieillissement cutané intrinsèque et/ou extrinsèque, ainsi que pour le traitement thérapeutique et prophylactique des effets nocifs des rayons ultraviolets sur la peau

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15781683

Country of ref document: EP

Kind code of ref document: A1

REEP Request for entry into the european phase

Ref document number: 2015781683

Country of ref document: EP